Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsChing‐Yao Yang, Chong‐Jen Yu, Wei‐Yu Liao et al.|European Journal of Cancer|2019Cited by 92
The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemiaLucy C. Fox, Andrew Grigg, Amy P. Holmes et al.|Blood Advances|2017Cited by 42
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibChing‐Yao Yang, Chong‐Jen Yu, Wei‐Yu Liao et al.|The Oncologist|2020Cited by 25
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational studyChing‐Yao Yang, Chong‐Jen Yu, Wei‐Yu Liao et al.|Journal of the Formosan Medical Association|2024Cited by 5
Spatial Proximity of Tumor Infiltrating Immune Cells Uncovers a Novel Insight in Pulmonary Lymphoepithelial CarcinomaWei‐Hsun Hsu, James C. Yang, Chia‐Chi Hsu et al.|Research Square|2022Cited by 0